TGT
40
9
TDC
68
-10
NUE
60
2
GME
59
-6
WAT
61
2
BIIB
43
11
T
45
-6
EQR
53
-6
LNC
40
-2
OI
42
4
BEN
48
-2
PFE
26
-2
HBAN
57
-3
AIG
45
-5
CNX
78
-5
ADP
66
-3
DFS
73
9
INTU
53
-3
FAST
57
-2
SLG
59
-4
TGT
40
9
TDC
68
-10
NUE
60
2
GME
59
-6
WAT
61
2
BIIB
43
11
T
45
-6
EQR
53
-6
LNC
40
-2
OI
42
4
BEN
48
-2
PFE
26
-2
HBAN
57
-3
AIG
45
-5
CNX
78
-5
ADP
66
-3
DFS
73
9
INTU
53
-3
FAST
57
-2
SLG
59
-4
Financhill
Back

LakeShore Biopharma 10K Form

Sell
27

LSB
LakeShore Biopharma

Last Price:
3.13
Seasonality Move:
-12.19%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive LSB News And Ratings

See the #1 stock for the next 7 days that we like better than LSB

LSB Financial Statistics

Sales & Book Value

Annual Sales: $80.21M
Cash Flow: $0
Price / Cash Flow: 0
Annual Sales: $0.82
Price / Book: 0

Profitability

EPS (TTM): -0.39800
Net Income (TTM): $-26.16M
Gross Margin: $63.74M
Return on Equity: 0%
Return on Assets: 0%

LakeShore Biopharma Earnings Forecast

Key LakeShore Biopharma Financial Ratios

  • The Gross Profit Margin over the past 4 years for LSB is 79.48%.
  • The Selling, General & Administrative Expenses for LSB have been equal to 74.66% of Gross Profit Margin.
  • The Research & Development expenses have been 52.81% of Revenue.
  • The Interest Expense is -10.23% of Operating Income.
  • The Net Earning history of LSB is -75.59% of Total Revenues.
  • Per Share Earnings over the last 4 years have been positive in 0 years.

LakeShore Biopharma Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: LSB
Website: lakeshorebio.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 0
Quick Ratio: 0

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

LSB Technical Analysis vs Fundamental Analysis

Sell
27
LakeShore Biopharma (LSB) is a Sell

Is LakeShore Biopharma a Buy or a Sell?